BACKGROUND:Massive transfusion protocols (MTPs) have become standard of care in the management of bleeding injured patients, yet strategies to guide them vary widely. We conducted a pragmatic, randomized clinical trial (RCT) to test the hypothesis that an MTP goal directed by the viscoelastic assay thrombelastography (TEG) improves survival compared with an MTP guided by conventional coagulation assays (CCA). METHODS: This RCT enrolled injured patients from an academic level-1 trauma center meeting criteria for MTP activation. Upon MTP activation, patients were randomized to be managed either by an MTP goal directed by TEG or by CCA (ie, international normalized ratio, fibrinogen, platelet count). Primary outcome was 28-day survival. RESULTS:One hundred eleven patients were included in an intent-to-treat analysis (TEG = 56, CCA = 55). Survival in the TEG group was significantly higher than the CCA group (log-rank P = 0.032, Wilcoxon P = 0.027); 20 deaths in the CCA group (36.4%) compared with 11 in the TEG group (19.6%) (P = 0.049). Most deaths occurred within the first 6 hours from arrival (21.8% CCA group vs 7.1% TEG group) (P = 0.032). CCA patients required similar number of red blood cell units as the TEG patients [CCA: 5.0 (2-11), TEG: 4.5 (2-8)] (P = 0.317), but more plasma units [CCA: 2.0 (0-4), TEG: 0.0 (0-3)] (P = 0.022), and more platelets units [CCA: 0.0 (0-1), TEG: 0.0 (0-0)] (P = 0.041) in the first 2 hours of resuscitation. CONCLUSIONS: Utilization of a goal-directed, TEG-guided MTP to resuscitate severely injured patients improves survival compared with an MTP guided by CCA and utilizes less plasma and platelet transfusions during the early phase of resuscitation.
RCT Entities:
BACKGROUND: Massive transfusion protocols (MTPs) have become standard of care in the management of bleeding injured patients, yet strategies to guide them vary widely. We conducted a pragmatic, randomized clinical trial (RCT) to test the hypothesis that an MTP goal directed by the viscoelastic assay thrombelastography (TEG) improves survival compared with an MTP guided by conventional coagulation assays (CCA). METHODS: This RCT enrolled injured patients from an academic level-1 trauma center meeting criteria for MTP activation. Upon MTP activation, patients were randomized to be managed either by an MTP goal directed by TEG or by CCA (ie, international normalized ratio, fibrinogen, platelet count). Primary outcome was 28-day survival. RESULTS: One hundred eleven patients were included in an intent-to-treat analysis (TEG = 56, CCA = 55). Survival in the TEG group was significantly higher than the CCA group (log-rank P = 0.032, Wilcoxon P = 0.027); 20 deaths in the CCA group (36.4%) compared with 11 in the TEG group (19.6%) (P = 0.049). Most deaths occurred within the first 6 hours from arrival (21.8% CCA group vs 7.1% TEG group) (P = 0.032). CCApatients required similar number of red blood cell units as the TEG patients [CCA: 5.0 (2-11), TEG: 4.5 (2-8)] (P = 0.317), but more plasma units [CCA: 2.0 (0-4), TEG: 0.0 (0-3)] (P = 0.022), and more platelets units [CCA: 0.0 (0-1), TEG: 0.0 (0-0)] (P = 0.041) in the first 2 hours of resuscitation. CONCLUSIONS: Utilization of a goal-directed, TEG-guided MTP to resuscitate severely injured patients improves survival compared with an MTP guided by CCA and utilizes less plasma and platelet transfusions during the early phase of resuscitation.
Authors: Michael P Chapman; Ernest E Moore; Christopher R Ramos; Arsen Ghasabyan; Jeffrey N Harr; Theresa L Chin; John R Stringham; Angela Sauaia; Christopher C Silliman; Anirban Banerjee Journal: J Trauma Acute Care Surg Date: 2013-12 Impact factor: 3.313
Authors: Steven L Spitalnik; Darrell Triulzi; Dana V Devine; Walter H Dzik; Anne F Eder; Terry Gernsheimer; Cassandra D Josephson; Daryl J Kor; Naomi L C Luban; Nareg H Roubinian; Traci Mondoro; Lisbeth A Welniak; Shimian Zou; Simone Glynn Journal: Transfusion Date: 2015-08-10 Impact factor: 3.157
Authors: I Raza; R Davenport; C Rourke; S Platton; J Manson; C Spoors; S Khan; H D De'Ath; S Allard; D P Hart; K J Pasi; B J Hunt; S Stanworth; P K MacCallum; K Brohi Journal: J Thromb Haemost Date: 2013-02 Impact factor: 5.824
Authors: Geoffrey R Nunns; Ernest E Moore; Gregory R Stettler; Hunter B Moore; Arsen Ghasabyan; Mitchell Cohen; Benjamin R Huebner; Christopher C Silliman; Anirban Banerjee; Angela Sauaia Journal: Surgery Date: 2018-04-27 Impact factor: 3.982
Authors: Hunter B Moore; Ernest E Moore; Matthew D Neal; Forest R Sheppard; Lucy Z Kornblith; Dominik F Draxler; Mark Walsh; Robert L Medcalf; Mitch J Cohen; Bryan A Cotton; Scott G Thomas; Christine M Leeper; Barbara A Gaines; Angela Sauaia Journal: Anesth Analg Date: 2019-09 Impact factor: 5.108
Authors: Hunter B Moore; Ernest E Moore; Michael P Chapman; Kevin McVaney; Gary Bryskiewicz; Robert Blechar; Theresa Chin; Clay Cothren Burlew; Fredric Pieracci; F Bernadette West; Courtney D Fleming; Arsen Ghasabyan; James Chandler; Christopher C Silliman; Anirban Banerjee; Angela Sauaia Journal: Lancet Date: 2018-07-20 Impact factor: 79.321
Authors: Jason M Samuels; Ernest E Moore; Christopher C Silliman; Anirban Banerjee; Mitchell J Cohen; Arsen Ghasabyan; James Chandler; Julia R Coleman; Angela Sauaia Journal: J Trauma Acute Care Surg Date: 2019-04 Impact factor: 3.313
Authors: Anirban Banerjee; Christopher C Silliman; Ernest E Moore; Monika Dzieciatkowska; Marguerite Kelher; Angela Sauaia; Kenneth Jones; Michael P Chapman; Eduardo Gonzalez; Hunter B Moore; Angelo D'Alessandro; Erik Peltz; Benjamin E Huebner; Peter Einerson; James Chandler; Arsen Ghasabayan; Kirk Hansen Journal: J Trauma Acute Care Surg Date: 2018-06 Impact factor: 3.313
Authors: Julia R Coleman; Ernest E Moore; Michael P Chapman; Anirban Banerjee; Christopher C Silliman; Arsen Ghasabyan; James Chandler; Jason M Samuels; Angela Sauaia Journal: Surgery Date: 2018-06-12 Impact factor: 3.982
Authors: Gregory R Stettler; Ernest E Moore; Geoffrey R Nunns; Jim Chandler; Erik Peltz; Christopher C Silliman; Anirban Banerjee; Angela Sauaia Journal: J Surg Res Date: 2018-04-11 Impact factor: 2.192